Inhibition of CCR2 causes monocyte retention in bone marrow and leads to depletion of monocytes in the peripheral circulation, reduction of monocyte recruitment to the primary tumor sites and metastatic foci, and consequent reduction of TAM number, resulting in tumor shrinkage and survival improvement (54–56). This evidence concerns the gene CCR2 and neoplasm.